Synapse

← James P. Allison

Papers by James P. Allison

Page 4 · newest first

  1. Cytotoxic T cells specific for alpha-myosin drive immunotherapy related myocarditis2022
  2. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy responseScience · 2021
  3. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinomaNature Communications · 2021
  4. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapyNature Communications · 2021
  5. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironmentJournal for ImmunoTherapy of Cancer · 2021
  6. Checkpoint Blockade + Chemotherapy: the Right Combination for AML?Blood Cancer Discovery · 2021
  7. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancerNature Communications · 2021
  8. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and NeckClinical Cancer Research · 2021
  9. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapyThe Journal of Experimental Medicine · 2021
  10. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancerJournal for ImmunoTherapy of Cancer · 2021
  11. First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid TumorsClinical Cancer Research · 2021
  12. The Next Decade of Immune Checkpoint TherapyCancer Discovery · 2021
  13. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic InterventionCancer Discovery · 2020
  14. Frontiers in cancer immunotherapy—a symposium reportAnnals of the New York Academy of Sciences · 2020
  15. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of ResponseBlood · 2020
  16. Single-cell Characterization of Acute Myeloid Leukemia and its Microenvironment Following PD-1 Blockade Based Therapy2020
  17. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunityJCI Insight · 2020
  18. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCCScience Translational Medicine · 2020
  19. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanomaNature Communications · 2020
  20. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancerScience Translational Medicine · 2020
  21. Comprehensive T cell repertoire characterization of non-small cell lung cancerNature Communications · 2020
  22. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancerJournal for ImmunoTherapy of Cancer · 2019
  23. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 StudyBlood · 2019
  24. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal ResponsesCancer Immunology Research · 2019
  25. Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapiesProceedings of the National Academy of Sciences · 2019
  26. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicitiesProceedings of the National Academy of Sciences · 2019
  27. Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethalityJCI Insight · 2019
  28. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophagesNeuro-Oncology · 2019
  29. Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated MannerCancer Immunology Research · 2019
  30. Characterization and Comparison of GITR Expression in Solid TumorsClinical Cancer Research · 2019
  31. Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular CarcinomaCancer Immunology Research · 2019
  32. Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—ResponseClinical Cancer Research · 2019
  33. TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletionProceedings of the National Academy of Sciences · 2019
  34. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?American Society of Clinical Oncology Educational Book · 2019
  35. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancerProceedings of the National Academy of Sciences · 2019
  36. The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaCancer · 2018
  37. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyCancer Discovery · 2018
  38. Fundamental Mechanisms of Immune Checkpoint Blockade TherapyCancer Discovery · 2018
  39. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human CancersClinical Cancer Research · 2018
  40. Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapyJournal of Clinical Investigation · 2018
  41. Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma.Journal of Clinical Oncology · 2018
  42. Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 BlockadeCancer Immunology Research · 2018
  43. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid MalignanciesClinical Cancer Research · 2017
  44. Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid LeukemiaBlood · 2017
  45. Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AMLBlood · 2017
  46. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patientsScience · 2017
  47. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genesSHILAP Revista de lepidopterología · 2017
  48. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical RecurrenceCancer Discovery · 2017
  49. The emerging role of immune checkpoint based approaches in AML and MDSLeukemia & lymphoma/Leukemia and lymphoma · 2017
  50. Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor ImmunityThe Journal of Immunology · 2017